RxSight (RXST) Receives a Buy from BTIG

In a report released today, Ryan Zimmerman from BTIG maintained a Buy rating on RxSight (RXSTResearch Report), with a price target of $24.00. The company’s shares closed today at $13.05.

According to TipRanks, Zimmerman is a 5-star analyst with an average return of 10.2% and a 47.77% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Intuitive Surgical, Medtronic, and Staar Surgical.

RxSight has an analyst consensus of Strong Buy, with a price target consensus of $20.50, a 57.09% upside from current levels. In a report released on January 9, Needham also reiterated a Buy rating on the stock with a $22.00 price target.

See today’s best-performing stocks on TipRanks >>

RXST market cap is currently $348.7M and has a P/E ratio of -5.28.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery.

Read More on RXST:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More